Biotechnology firm Neogene Therapeutics has signed an exclusive, global license agreement with the National Cancer Institute (NCI) for a portfolio of T cell receptor (TCRs) targeting KRAS and TP53 mutations for the treatment of patients suffering with cancer.
Portfolio of TCRs developed in the laboratory of immunotherapy pioneer Steven Rosenberg, M.D., Ph.D. at the National Cancer Institute, combined with Neogene's proprietary TCR isolation platform, provides
The company has worldwide rights to develop, manufacture, and commercialize the KRAS and TP53 mutation targeting TCR portfolio of T-cell therapy candidates.
Jeito Capital: JEITO CAPITAL BECOMES A KEY PLAYER IN THE FINANCING OF LIFE SCIENCES IN EUROPE WITH THE CLOSING OF JEITO I AT €534 MILLION ($630 MILLION) finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
JEITO CAPITAL BECOMES A KEY PLAYER IN THE FINANCING OF LIFE SCIENCES IN EUROPE WITH THE CLOSING ... apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.